Free Trial

CryoPort (CYRX) Competitors

CryoPort logo
$7.58 -0.01 (-0.20%)
As of 12:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CYRX vs. JANX, BHVN, ANIP, MESO, EWTX, TVTX, CVAC, PAHC, ABCL, and CALT

Should you be buying CryoPort stock or one of its competitors? The main competitors of CryoPort include Janux Therapeutics (JANX), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), CureVac (CVAC), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.

CryoPort vs. Its Competitors

CryoPort (NASDAQ:CYRX) and Janux Therapeutics (NASDAQ:JANX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Janux Therapeutics has a net margin of 0.00% compared to CryoPort's net margin of -50.15%. Janux Therapeutics' return on equity of -9.29% beat CryoPort's return on equity.

Company Net Margins Return on Equity Return on Assets
CryoPort-50.15% -11.03% -5.54%
Janux Therapeutics N/A -9.29%-8.89%

Janux Therapeutics has lower revenue, but higher earnings than CryoPort. Janux Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CryoPort$232.13M1.64-$114.76M-$2.34-3.24
Janux Therapeutics$10.59M140.20-$68.99M-$1.36-18.45

CryoPort has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500.

CryoPort currently has a consensus target price of $10.88, suggesting a potential upside of 43.28%. Janux Therapeutics has a consensus target price of $95.25, suggesting a potential upside of 279.60%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than CryoPort.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CryoPort
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Janux Therapeutics
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.09

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 10.1% of CryoPort shares are owned by company insiders. Comparatively, 29.4% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, CryoPort had 6 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for CryoPort and 0 mentions for Janux Therapeutics. CryoPort's average media sentiment score of 0.05 beat Janux Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media.

Company Overall Sentiment
CryoPort Neutral
Janux Therapeutics Neutral

Summary

Janux Therapeutics beats CryoPort on 11 of the 17 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYRX vs. The Competition

MetricCryoPortTRANS IndustryTransportation SectorNASDAQ Exchange
Market Cap$378.23M$5.78B$7.18B$8.98B
Dividend YieldN/A2.30%914.35%4.04%
P/E Ratio-3.2210.6412.8920.16
Price / Sales1.641.21347.83124.91
Price / CashN/A10.767.4757.86
Price / Book1.022.962.115.57
Net Income-$114.76M$189.74M$563.51M$248.52M
7 Day Performance1.95%-1.72%0.47%5.05%
1 Month Performance8.98%1.11%4.24%6.98%
1 Year Performance26.42%-0.74%5.42%21.36%

CryoPort Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYRX
CryoPort
2.469 of 5 stars
$7.59
-0.1%
$10.88
+43.3%
+19.7%$378.23M$232.13M-3.221,186Analyst Forecast
JANX
Janux Therapeutics
2.0586 of 5 stars
$23.96
-2.0%
$95.25
+297.5%
-38.0%$1.42B$10.59M-17.6230
BHVN
Biohaven
3.1907 of 5 stars
$13.81
-5.6%
$58.46
+323.3%
-59.7%$1.41BN/A-1.48239
ANIP
ANI Pharmaceuticals
3.4101 of 5 stars
$64.91
-0.6%
$80.13
+23.4%
+4.3%$1.41B$614.38M-51.11600
MESO
Mesoblast
1.9853 of 5 stars
$10.53
-1.4%
$18.00
+70.9%
+35.2%$1.35B$5.90M0.0080
EWTX
Edgewise Therapeutics
2.6375 of 5 stars
$12.61
-3.2%
$40.00
+217.2%
-37.8%$1.33BN/A-8.1460
TVTX
Travere Therapeutics
3.3292 of 5 stars
$14.60
-2.7%
$32.14
+120.2%
+75.5%$1.30B$273.53M-5.20460Gap Up
CVAC
CureVac
4.5018 of 5 stars
$5.41
-0.7%
$6.83
+26.3%
+73.2%$1.21B$523.70M5.88880
PAHC
Phibro Animal Health
3.6777 of 5 stars
$29.90
+6.8%
$24.40
-18.4%
+71.9%$1.21B$1.02B38.331,940News Coverage
Analyst Upgrade
High Trading Volume
ABCL
AbCellera Biologics
2.5525 of 5 stars
$4.03
+6.1%
$7.50
+86.1%
+41.5%$1.20B$28.83M-7.20500News Coverage
Analyst Forecast
Analyst Revision
Gap Up
High Trading Volume
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180

Related Companies and Tools


This page (NASDAQ:CYRX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners